In the present study, we engineered an adenovirus coding for a human vIL-2 protein (Ad5/3-E2F-d24-vIL2) to promote anti-tumor response through the selective stimulation of effector T cells in the context of immunosuppressive solid tumors. The gene discussed is EZR; the disease is neoplasm.